Notify me when Ph.D. Jay R. Luly files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc. | Common Stock, par value $0.01 per share | 7.7% | $7,904,778 | 1,703,616 | Jay R. Luly, Ph.D. | 12 Feb 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|